| Literature DB >> 34069070 |
Lu Yu1, Jiyan Chi1, Lingling Xiao1, Jie Li1, Zhangfei Tang1, Shuming Tan1, Pei Li1,2.
Abstract
A series of novel thiochromanone derivatives containing a sulfonyl hydrazone moiety were designed and synthesized. Their structures were determined by 1H-NMR, 13C-NMR, and HRMS. Bioassay results showed that most of the target compounds revealed moderate to good antibacterial activities against Xanthomonas oryzae pv. oryzae, Xanthomonas oryzae pv. oryzicolaby, and Xanthomonas axonopodis pv. citri. Compound 4i had the best inhibitory activity against Xanthomonas oryzae pv. oryzae, Xanthomonas oryzae pv. oryzicolaby, and Xanthomonas axonopodis pv. citri, with the EC50 values of 8.67, 12.65, and 10.62 μg/mL, which were superior to those of Bismerthiazol and Thiodiazole-copper. Meanwhile, bioassay results showed that all of the target compounds proved to have lower antifungal activities against Sclerotinia sclerotiorum, Fusarium oxysporum, Gibberella zeae, Rhizoctonia solani, Verticillium dahlia, and Botrytis cinerea than those of Carbendazim.Entities:
Keywords: antibacterial activity; antifungal activity; sulfonyl hydrazone; thiochromanone
Year: 2021 PMID: 34069070 PMCID: PMC8156870 DOI: 10.3390/molecules26102925
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthesis of compounds 4a–4r.
In vitro antibacterial activities of the target compounds 4a against Xanthomonas oryzae pv. oryzae, Xanthomonas oryzae pv. oryzicolaby, and Xanthomonas axonopodis pv. citri at 200 and 100 μg/mL.
| Compounds | Inhibition Rate (%) a | |||||
|---|---|---|---|---|---|---|
|
|
|
| ||||
| 200 (μg/mL) | 100 (μg/mL) | 200 (μg/mL) | 100 (μg/mL) | 200 (μg/mL) | 100 (μg/mL) | |
|
| 82 ± 1.54 * | 66 ± 2.78 * | 63 ± 2.05 | 57 ± 1.98 * | 70 ± 1.07 * | 60 ± 2.67 * |
|
| 74 ± 1.89 | 54 ± 2.43 | 58 ± 1.23 | 45 ± 2.06 * | 62 ± 1.78 | 50 ± 1.98 * |
|
| 96 ± 1.75 * | 85 ± 1.45 * | 84 ± 2.07 * | 71 ± 1.83 * | 92 ± 1.15 * | 80 ± 1.43 * |
|
| 76 ± 2.07 * | 60 ± 1.64 * | 55 ± 1.98 | 40 ± 2.98 | 60 ± 1.09 | 52 ± 1.82 * |
|
| 62 ± 1.12 | 50 ± 1.81 | 50 ± 2.22 | 39 ± 1.83 | 56 ± 1.89 | 48 ± 1.23 * |
|
| 90 ± 1.78 * | 78 ± 1.06 * | 76 ± 2.22 * | 65 ± 1.45 * | 84 ± 1.81 * | 72 ± 1.63 * |
|
| 100 ± 0.67 * | 90 ± 1.82 * | 93 ± 0.21 * | 85 ± 2.05 * | 100 ± 1.04 * | 87 ± 1.39 * |
|
| 100 ± 1.29 * | 84 ± 1.81 * | 90 ± 1.87 * | 80 ± 2.01 * | 96 ± 1.02 * | 90 ± 1.27 * |
|
| 100 ± 0.78 * | 100 ± 0.67* | 96 ± 2.10 * | 90 ± 1.06 * | 100 ± 1.01 * | 96 ± 1.06 * |
|
| 100 ± 0.67 * | 94 ± 0.98 * | 85 ± 1.09 * | 72 ± 2.09 * | 92 ± 1.85 * | 80 ± 1.03 * |
|
| 87 ± 2.07 * | 75 ± 1.72 * | 70 ± 3.06 * | 54 ± 2.01 * | 76 ± 2.06 * | 63 ± 1.83 * |
|
| 100 ± 0.98 * | 100 ± 2.52 * | 90 ± 2.05 * | 80 ± 1.76 * | 100 ± 0.97 * | 90 ± 1.82 * |
|
| 72 ± 1.65 | 56 ± 2.73 | 50 ± 1.13 | 40 ± 2.29 | 60 ± 1.45 | 50 ± 2.21 * |
|
| 65 ± 1.89 | 46 ± 2.48 | 45 ± 1.54 | 37 ± 1.90 | 52 ± 1.43 | 42 ± 1.41 * |
|
| 86 ± 1.43 * | 75 ± 1.39 * | 75 ± 2.80 * | 60 ± 1.11 * | 82 ± 1.43 * | 70 ± 1.50 * |
|
| 66 ± 2.54 | 59 ± 1.69 * | 45 ± 2.01 | 32 ± 1.05 | 50 ± 1.32 | 37 ± 1.22 |
|
| 52 ± 1.12 | 43 ± 1.54 | 40 ± 1.65 | 30 ± 1.62 | 48 ± 1.60 | 36 ± 1.46 |
|
| 80 ± 1.15 * | 70 ± 2.22 * | 71 ± 0.98 * | 56 ± 2.20 * | 76 ± 1.07 * | 62 ± 3.38 * |
| Bismerthiazol | 70 ± 0.89 | 52 ± 1.62 | 57 ± 5.56 | 35 ± 6.76 | 55 ± 2.43 | 32 ± 3.26 |
| Thiodiazole-copper | 63 ± 2.71 | 45 ± 2.65 | 35 ± 4.31 | 15 ± 2.11 | 36 ± 1.56 | 16 ± 2.19 |
a Average of three replicates (mean ± SD). Asterisk (*) indicated the inhibition rates of the target compounds with significant difference at p < 0.05 compared with those of positive controls Bismerthiazol and Thiodiazole-copper.
The EC50 values of some of the target compounds against Xanthomonas oryzae pv. oryzae, Xanthomonas oryzae pv. oryzicolaby, and Xanthomonas axonopodis pv. citri.
| Compounds | EC50 (μg/mL) a | ||
|---|---|---|---|
|
|
|
| |
|
| 23 ± 2.19 * | 35 ± 3.38 * | 28 ± 1.95 * |
|
| 32 ± 3.04 * | 46 ± 2.90 * | 38 ± 0.93 * |
|
| 18 ± 2.75 * | 27 ± 2.17 * | 21 ± 3.89 * |
|
| 15 ± 2.19 * | 24 ± 1.98 * | 19 ± 1.87 * |
|
| 8 ± 1.89 * | 12 ± 2.06* | 10 ± 2.04 * |
|
| 13 ± 3.07 * | 22 ± 1.98 * | 17 ± 2.28 * |
|
| 12 ± 1.89 * | 18 ± 1.56 * | 13 ± 2.06 * |
| Bismerthiazol | 84 ± 2.89 | 151 ± 5.98 | 145 ± 2.65 |
| Thiodiazole-copper | 109 ± 3.01 | 269 ± 7.11 | 230 ± 2.46 |
a Average of three replicates (mean ± SD). Asterisk (*) indicated the inhibition rates of the target compounds with significant difference at p < 0.05 compared with those of positive controls Bismerthiazol and Thiodiazole-copper.
In vitro antifungal activities of the target compounds 4a–4r against Sclerotinia sclerotiorum, Fusarium oxysporum, Gibberella zeae, Rhizoctonia solani, Verticillium dahlia, and Botrytis cinerea at 50 μg/mL.
| Compounds | Inhibition Rate (%) a | |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
| 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 12 ± 2.01 * | 0 | 18 ± 1.76 * | 21 ± 1.67 * |
|
| 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 0 | 0 | 0 | 0 |
|
| 25 ± 3.36 * | 34 ± 1.98 * | 0 | 16 ± 1.36 * | 28 ± 2.20 * | 41 ± 2.16 * |
|
| 20 ± 0.65 * | 11 ± 1.52 * | 0 | 0 | 0 | 0 |
|
| 45 ± 3.21 * | 38 ± 2.15 * | 21 ± 1.51 * | 38 ± 2.50 * | 45 ± 1.54 * | 52 ± 1.62 * |
|
| 28 ± 2.59 * | 29 ± 2.18 * | 4 ± 2.12 * | 20 ± 1.62 * | 30 ± 2.19 * | 45 ± 1.56 * |
|
| 0 | 0 | 0 | 0 | 0 | 14 ± 2.05 * |
|
| 35 ± 1.65 * | 32 ± 1.54 * | 16 ± 1.95 * | 29 ± 1.52 * | 38 ± 2.54 * | 34 ± 1.49 * |
|
| 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 0 | 3 ± 1.16 * | 0 | 12 ± 3.71 * |
|
| 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 0 | 0 | 0 | 0 |
| Carbendazim | 100 | 100 | 100 | 47 ± 2.26 | 79 ± 3.18 | 57 ± 2.19 |
a Average of three replicates (mean ± SD). Asterisk (*) indicated the inhibition rates of the target compounds with significant difference at p < 0.05 compared with those of positive control Carbendazim.